Author/Authors :
Yousefnia, Hassan Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran , Bitarafan-Rajabi, Ahmad Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran , Pedram, Mir Sepehr Department of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran , Zolghadri, Samaneh Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran , Bahrami-Samani, Ali Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran , Jalilian, Amir Reza Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran , Mazidi, Mohammad Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran , Darbandi Azad, Amir Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran , Ghannadi-Maragheh, Mohammad Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
Abstract :
Introduction: Recently, due to the special characteristics of 166Ho and chitosan, 166Ho-chitosan complex was developed for
treatment of tumors such as hepatocellular carcinoma. This complex has been lately prepared with high radiochemical purity
in our lab. The preclinical studies of the complex however should be performed to evaluate the tracer concentration in target
and normal tissues before human use.
Methods: In this study, 166Ho-chitosan was prepared and its preclinical studies for treatment of hepatocellular carcinoma
was carried out by injection of the radiopharmaceutical into the rabbit`s liver via two different methods, surgery and
venography. Leakage of the injected activity from the injection site in the rabbit organs was investigated using SPECT and
SPECT-CT imaging up to 24 hours.
Results: Both SPECT and SPECT-CT imaging of the rabbits showed that there was no significant leakage of the injected
activity. Almost all the activity would remain in the injection site at least 24 h post injection.
Conclusion: Considering all of the excellent features of the complex, this radiopharmaceutical is suggestive for treatment of
hepatocellular carcinoma by radioembolization method.
Keywords :
Chitosan , Holmium-166 , Hepatocellular carcinoma , SPECT , SPECT/CT
